Senolytics reduce coronavirus-related mortality in old mice.
Camell CD, Yousefzadeh MJ, Zhu Y, Prata LGPL, Huggins MA, Pierson M, Zhang L, O'Kelly RD, Pirtskhalava T, Xun P, Ejima K, Xue A, Tripathi U, Espindola-Netto JM, Giorgadze N, Atkinson EJ, Inman CL, Johnson KO, Cholensky SH, Carlson TW, LeBrasseur NK, Khosla S, O'Sullivan MG, Allison DB, Jameson SC, Meves A, Li M, Prakash YS, Chiarella SE, Hamilton SE, Tchkonia T, Niedernhofer LJ, Kirkland JL, Robbins PD. · 2021
Read Senolytics reduce coronavirus-related mortality in old mice. by Camell CD, Yousefzadeh MJ, Zhu Y, Prata LGPL, Huggins MA, Pierson M, Zhang L, O'Kelly RD, Pirtskhalava T, Xun P, Ejima K, Xue A, Tripathi U, Espindola-Netto JM, Giorgadze N, Atkinson EJ, Inman CL, Johnson KO, Cholensky SH, Carlson TW, LeBrasseur NK, Khosla S, O'Sullivan MG, Allison DB, Jameson SC, Meves A, Li M, Prakash YS, Chiarella SE, Hamilton SE, Tchkonia T, Niedernhofer LJ, Kirkland JL, Robbins PD. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8607935.txt.
Introduction
Camell and co-authors test drugs that clear aged cells in old mice infected with a coronavirus. Aged, or senescent, cells build up with age and release harmful signals. The team found these cells react strongly to SARS-CoV-2. Their signals also weaken virus defense in nearby healthy cells and raise viral entry proteins.
Old mice got a virus related to SARS-CoV-2. Treatment with senolytic drugs cut the load of aged cells. Death rates fell in the treated mice. Their antiviral antibody levels also rose. The work suggests that clearing aged cells could help older patients face severe viral illness. It links cell aging to the high risk seen in old age.
Catalog record
| CREATOR | Camell CD, Yousefzadeh MJ, Zhu Y, Prata LGPL, Huggins MA, Pierson M, Zhang L, O'Kelly RD, Pirtskhalava T, Xun P, Ejima K, Xue A, Tripathi U, Espindola-Netto JM, Giorgadze N, Atkinson EJ, Inman CL, Johnson KO, Cholensky SH, Carlson TW, LeBrasseur NK, Khosla S, O'Sullivan MG, Allison DB, Jameson SC, Meves A, Li M, Prakash YS, Chiarella SE, Hamilton SE, Tchkonia T, Niedernhofer LJ, Kirkland JL, Robbins PD. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 77 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Senolytics reduce coronavirus-related mortality in old mice By Christina D Camell, Matthew J Yousefzadeh, Yi Zhu, Larissa G P Langhi Prata, Matthew A Huggins, Mark Pierson, Lei Zhang, Ryan D O’Kelly, Tamar Pirtskhalava, Pengcheng Xun, Keisuke Ejima, Ailing Xue Published in: Science (New York, N.y.) DOI: 10.1126/science.abe4832 ABSTRACT Senescent cells exacerbate COVID-19 Cellular senescence is a state elicited in response to stress signals and is associated with a damaging secretory phenotype. The number of senescent cells increases with advanced age and this in turn drives age-related diseases. Camell et al. show that senescent cells have an amplified inflammatory response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (see the Perspective by Cox and Lord). This response is communicated to nonsenescent cells, suppressing viral defense mechanisms and increasing the expression of viral entry proteins. In old mice infected with a SARS-CoV-2–related virus, treatment with senolytics to reduce the senolytic cell burden reduced mortality and increased antiviral antibodies. Science, abe4832, this issue p. eabe4832; see also abi4474, p. 281 Old age is the greatest risk factor by orders of magnitude for most chronic diseases, including cancers, diabetes, cardiovascular disease, and Alzheimer’s disease. Aging also predisposes to geriatric syndromes and loss of physical resilience. The current COVID-19 pandemic has illuminated the particular vulnerability of the elderly and those with underlying geriatric syndromes to increased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–mediated mortality (1–5). Thus, approaches to extend health span and enhance physical resilience could reduce the rate of mortality in elderly COVID-19 patients. Cellular senescence has emerged as one of the mechanisms that drives aging and age-related diseases that is most tractable to therapeutically target (6, 7). Senescence is a cell fate elicited in response to external and internal cellular stress signals, established through transcription factor cascades that can include p16INK4a/retinoblastoma protein and/or p53/p21CIP1, which cause extensive changes in gene expression, histone modifications, organelle function, elevated protein production, and profound morphologic and metabolic shifts (8, 9). A substantial fraction of senescent cells (SnCs) release inflammatory factors, chemokines, growth factors, proteases, bioactive lipids, extracellular vesicles, and procoagulant factors, called the senescence-associated secretory phenotype (SASP) (6). Senescence is a robust tumor suppressor mechanism, with the SASP acting as a chemoattractant-stimulating immune cell–mediated clearance of senescent and neighboring cells. However, with advancing age and many chronic diseases, SnCs accumulate in most tissues, presumably because of inefficient SnC removal by the immune system and resistance to cell death. This accumulation drives chronic sterile inflammation, which in turn drives loss of resilience and predisposition to many diseases (10). SnCs can interfere with the immune system and the ability of immune cells to remove them. For example, the SASP factors interleukin-6 (IL-6), monocyte chemotactic protein–1 (MCP-1), and chemokine (C-C motif) ligand 11 (CCL11) alter myeloid cell migration; interferon γ-induced protein 10 (IP10)/C-X-C motif chemokine 10 (CXCL10) depletes critical T lymphocyte subsets; and matrix metalloproteinases cleave fatty acid synthase (FAS) ligand and other immune system regulators (11). The SASP can drive fibrosis (11). SnCs have been demonstrated to play a causal role in aging and age-related diseases in preclinical models. Transplanting SnCs into young mice causes an accelerated aging-like state, whereas genetic or pharmacologic selective killing of SnCs attenuates disease, improves physical function, and delays all-cause mortality in older mice (12–14). Factors that are common components of the SASP are linked to prolonged disease, hyperinflammation/cytokine storm/acute respiratory distress syndrome (ARDS), myocarditis with troponin leak, T cell deficiencies, clotting, delirium, and multi-organ failure in SARS-CoV-2 patients (15). Also, a signature of the SASP factors IL-6, IL-10, and IP10 in COVID-19 patients appears to predict clinical progression (16). However, it is not known whether SnCs and their pro-inflammatory SASP contribute to the increased mortality observed in the elderly and chronically diseased after infection. Initially, to determine whether SnCs have an altered response to pathogen exposure compared with healthy cells, we treated irradiation-induced senescent human preadipocytes and non-SnCs with the pathogen-associated molecular pattern (PAMP) factor lipopolysaccharide (LPS). LPS stimulated expression of IL1α, IL1β, IL6, MCP1, and PAI2 in non-SnCs (Fig. 1A, fig. S1, and table S1) but did not significantly alter levels of p16INK4a or p21CIP1. Expression of these SASP factors as well as IL10 and PAI1 were all significantly increased by LPS in SnCs relative to untreated SnCs and relative to LPS-treated non-SnCs, suggesting that PAMPs exacerbate the SASP and that SnCs can amplify the inflammatory response to PAMPs. To determine whether a similar effect occurs in vivo, young and aged wild-type (WT) mice were challenged with LPS. Senescence and SASP markers were measured 24 hours after treatment. Although expression of the senescence markers p16Ink4a and p21Cip1 was not affected at this early time point, LPS exposure stimulated a significant increase in expression of Il1α, Il1β, Il6, Il10, Mcp1, Tnfα, Pai1, and Pai2 in liver (Fig. 1B) and kidney (fig. S2) of aged compared with young mice. Furthermore, LPS challenge significantly increased levels of the SASP factors IL-6, MCP-1, and tumor necrosis factor–α (TNFα) in the serum of old mice (Fig. 1C). To confirm the effect of LPS on aged mice with an increased SnC burden, we also treated progeroid Ercc1–/∆ mice (fig. S3)—which express high levels of senescence and SASP markers in the same tissues and to the same extent as occurs in WT mice, albeit much earlier in life (17)—acutely with LPS. Senescence and SASP markers were measured 24 hours after treatment. Although expression of senescence markers p16Ink4a and p21Cip1 was not affected at this early time point, LPS significantly increased expression of SASP factors (Il1α, Il1β, Il6, Tnfα, and Mcp1) in kidney and liver of the progeroid mice relative to age-matched WT controls (fig. S3) and significantly increased levels of circulating IL-6 and MCP-1 (fig. S3). On the basis of these results, we hypothesized that SnCs exposed to pathogen-associated signals contribute to hyperinflammation and cytokine storm after infection with pathogens. [Figure: The SASP is amplified by PAMP factors.(A) Human adipocyte progenitors isolated from subcutaneous fat biopsies were induced to undergo senescence with 10 gray (Gy) of ionizing radiation (SnC) or not (non-SnC) (n = 5 subjects). Cells were treated with 10 ng of the prototype PAMP LPS for 3 hours before RNA isolation. Gene expression was measured with quantitative PCR, and the expression in LPS-treated cells was normalized to vehicle-treated samples. Means ± SEM. Statistical significance was calculated by using a mixed effect model for the effect of LPS on SnCs and its differential effects on SnCs compared with non-SnCs. Details are available in table S1. Arrows and asterisks: gray, vehicle-treated SnCs versus non-SnCs; black, LPS-treated SnCs versus non-SnCs; red, SnCs ± LPS. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (B) Young (2-month-old) and old (26-month-old) mice were treated with phosphate-buffered saline (PBS) (n = 5 young and 5 old) or LPS (n = 4 young and 3 old), and tissues were collected 24 hours later. RNA was isolated from liver, and gene expression measured by means of quamtitative PCR. Expression in LPS-treated mice was normalized to vehicle-treated animals. Means ± SEM, two-way analysis of variance (ANOVA) and post hoc comparison Tukey’s honestly significant difference used to compare the two animal cohorts within a treatment group. Arrows and asterisks: gray, vehicle-treated old versus young;